Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development, manufacturing, and commercialization of next-generation engineered T‑cell therapies for the treatment of cancer. The company operates within the cell and gene therapy and oncology biotechnology industries, with a primary emphasis on hematologic malignancies. Autolus generates value through proprietary chimeric antigen receptor T‑cell (CAR‑T) platforms designed to enhance safety, persistence, and efficacy compared with earlier CAR‑T technologies.
The company’s lead product candidate is obecabtagene autoleucel (obe‑cel, also known as AUTO1), a CD19‑directed CAR‑T therapy developed for adult patients with relapsed or refractory B‑cell acute lymphoblastic leukemia (B‑ALL). Autolus was founded in 2014 as a spin‑out from University College London to commercialize academic advances in engineered T‑cell therapies, and it has since evolved into a vertically integrated CAR‑T developer with in‑house manufacturing and clinical capabilities.
Business Operations
Autolus operates as a single integrated biotechnology business with multiple clinical and preclinical programs built on its proprietary CAR‑T cell therapy platform. Revenue generation to date has been primarily driven by equity financing and strategic collaborations, as the company transitioned from a development-stage organization toward commercial operations following regulatory approval of its lead therapy.
Core operations include in‑house T‑cell engineering, clinical development, regulatory affairs, and manufacturing. The company controls a commercial-scale manufacturing facility in the United Kingdom, supporting both clinical supply and initial commercial launch. Autolus maintains strategic collaborations and licensing arrangements related to specific CAR constructs and manufacturing technologies, while remaining fully integrated rather than relying on contract manufacturing for its lead programs.
Strategic Position & Investments
Autolus’s strategic direction centers on establishing obe‑cel as a differentiated therapy in CD19‑positive leukemias and expanding its pipeline into additional hematologic indications using modular CAR designs. A key strategic milestone was the regulatory approval of Aucatzyl (the commercial name for obecabtagene autoleucel) in the United States, positioning Autolus to transition from a development-stage company to a commercial-stage biotechnology firm.
Beyond its lead program, Autolus is investing in earlier-stage candidates targeting antigens such as CD22 and dual-antigen approaches aimed at reducing relapse and toxicity. The company continues to allocate capital toward manufacturing scale-up, post‑approval clinical commitments, and next-generation CAR technologies designed to improve persistence and control of engineered T cells.
Geographic Footprint
Autolus is headquartered in London, United Kingdom, with its primary research, development, and manufacturing operations based in the UK. The company has established a significant operational presence in the United States, which represents its most important commercial market following regulatory approval.
The company’s clinical trials, regulatory activities, and commercial planning extend across North America and Europe, reflecting its focus on major developed healthcare markets. While Autolus does not maintain broad commercial operations across all continents, its therapies are designed for global applicability, and international expansion remains a longer-term objective.
Leadership & Governance
Autolus was founded by academic immunologists with deep expertise in CAR‑T science, and its leadership team combines scientific founders with executives experienced in biotechnology commercialization. The company’s governance emphasizes disciplined capital allocation, clinical differentiation, and long-term value creation through proprietary technology platforms.
Key executives include:
- Christian Itin – Chief Executive Officer
- Martin Pule – Founder and Chief Scientific Officer
- Andrew Oakley – Chief Financial Officer
The leadership team’s stated strategic vision focuses on building a fully integrated cell therapy company capable of delivering safer, more durable CAR‑T treatments while maintaining control over manufacturing quality and intellectual property.